Functional Dyspepsia Drug Pipeline — PatSnap Eureka
Acotiamide, Fundus Relaxants & Rome IV–Targeted Functional Dyspepsia Therapies
Functional dyspepsia affects approximately 1 in 10 individuals globally. PatSnap Eureka maps the full FD drug pipeline — from approved prokinetics to emerging duodenal-targeted biologics — stratified by Rome IV subtype.
A Heterogeneous Disorder Requiring Subtype-Stratified Treatment
Functional dyspepsia is classified under the Rome IV criteria into two principal subtypes — postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) — each underpinned by distinct pathophysiological mechanisms. Retrieved data from Hyogo College of Medicine confirm that under Rome IV, PDS prevalence increases to 64% (versus 38% under Rome III) while overlap with EPS decreases to 17% (versus 43%), suggesting Rome IV better isolates distinct pathophysiological entities for targeted therapeutic approaches.
Cardinal mechanisms identified across this dataset include: impaired gastric accommodation and delayed gastric emptying, visceral hypersensitivity, duodenal mucosal barrier dysfunction, duodenal eosinophilia, Helicobacter pylori–associated inflammation, altered GI peptide signaling (ghrelin, motilin, somatostatin), and gut-brain axis dysregulation. The duodenum has emerged as a central pathogenic locus, with Tohoku University data showing that EPS patients display reduced transepithelial electrical resistance (TEER) in duodenal mucosa under acidic pH conditions — implicating mucosal barrier dysfunction and acid hypersensitivity as EPS-specific targets.
GI peptides including ghrelin, motilin, and somatostatin are highlighted as modulators of gastric motility and emptying. Interstitial cells of Cajal (ICC) — gastrointestinal pacemaker cells regulated by the c-kit/stem cell factor axis — are identified as an emerging therapeutic target for herbal-based FD treatments. The PatSnap life sciences intelligence platform enables researchers to map these mechanistic clusters across global patent and literature databases.
Key Efficacy & Diagnostic Data Visualised
All data points derived from clinical trial reports, meta-analyses, and guideline publications retrieved via PatSnap Eureka.
Acotiamide vs Placebo: Phase III Responder Rates
Acotiamide 100 mg TID achieved 52.2% OTE responder rate vs 34.8% for placebo in meal-related FD symptoms (Sakura Life Clinic, Japan).
Rome IV vs Rome III: FD Subtype Reclassification
Rome IV increases PDS prevalence to 64% (from 38%) and reduces PDS-EPS overlap to 17% (from 43%), better isolating distinct pathophysiological entities.
Acotiamide Meta-Analysis: Risk Ratio by FD Subtype
Pooled analysis of 7 RCTs shows acotiamide efficacy is driven by PDS (RR 1.29) rather than EPS (RR 0.92, non-significant), confirming subtype specificity.
DA-9701 (Motilitone): Multi-Target Mechanism Profile
DA-9701 simultaneously addresses four FD pathophysiological domains, illustrating why multi-target botanical agents are gaining mechanistic credibility over single-target approaches.
Pharmacological Approaches Across the FD Pipeline
Six distinct drug classes address functional dyspepsia through complementary mechanisms — from approved prokinetics to early-stage microbiome interventions.
Acotiamide — First-in-Class Muscarinic/AChE Dual Mechanism
Acotiamide is a first-in-class muscarinic receptor antagonist and acetylcholinesterase inhibitor that enhances acetylcholine release at the gastric neuromuscular junction. Unlike dopamine D2 or serotonin receptor-targeting prokinetics, acotiamide operates selectively within the stomach through dual cholinergic enhancement, resulting in improved gastric accommodation and accelerated emptying. A Phase III head-to-head trial found acotiamide non-inferior to mosapride (a 5-HT4 agonist) for FD-PDS. A novel extended-release (ER) formulation — acotiamide 300 mg once daily — was evaluated in a Phase III multicenter Indian study as a clinically equivalent alternative to the standard TID regimen.
✓ Approved: Japan, India · ER formulation in Phase IIIDA-9701 (Motilitone) — Multi-Target Botanical Agent
DA-9701, formulated from Corydalis Tuber and Pharbitidis Semen, acts through multiple simultaneous mechanisms: prokinetic effects, fundus relaxation via dopamine D2 partial agonism and 5-HT4 agonism, visceral analgesia, and antinociception. A non-inferiority multicenter trial showed DA-9701 (30 mg TID) was non-inferior to itopride (50 mg TID) across 464 FD patients over 4 weeks. A separate trial versus pantoprazole among 389 patients confirmed DA-9701's clinical utility. Gachon University researchers argue that "current medicines for FD targeting a single pathway have failed to show satisfactory efficacy," positioning multi-target botanical agents as a superior design paradigm.
✓ Approved Korea 2011 · 464-patient RCTPPIs and PCABs — Preferentially Effective in EPS
Acid suppression is more effective in EPS than PDS, mechanistically explained by EPS-specific duodenal mucosal barrier vulnerability to acidic pH. The 2021 Japanese Society of Gastroenterology guidelines endorse acid suppression with PPIs recommended particularly for EPS. The potassium-competitive acid blocker (PCAB) vonoprazan (20 mg once daily) demonstrated symptom improvement across FD, non-erosive reflux disease, and reflux esophagitis cohorts in a Juntendo University retrospective study. A prospective comparison (India) showed acotiamide + rabeprazole was superior to double-dose rabeprazole monotherapy in PPI-refractory GERD/FD overlap patients.
Vonoprazan under expanded FD evaluation5-HT Receptor Agonists — Class-Level Safety Constraints
A meta-analysis from Hangzhou Seventh People's Hospital pooling 10 RCTs (892 patients in serotonin agonist arms, 640 placebo) evaluated cisapride, mosapride, tegaserod, and tandospirone citrate in FD. Although serotonin receptor agonists showed collective efficacy signals, significant heterogeneity between studies complicated effect size interpretation. Tegaserod (a 5-HT4 selective agonist) was investigated in a pilot multicenter study from the University of Wisconsin, demonstrating improvements in early satiety, postprandial fullness, and bloating in women with FD and PPI-treated heartburn. Class-level safety concerns (cisapride withdrawn; tegaserod restricted) have constrained this modality.
⚠ Class safety constraints limit developmentGhrelin & Motilin Receptor Agonists — Pipeline Direction
Ghrelin and motilin receptor agonists are identified as a pipeline direction for FD, particularly for PDS involving delayed gastric emptying. A systematic review from KU Leuven on GI peptides in FD and gastroparesis concludes that while absolute levels of ghrelin and motilin do not consistently differ between FD and controls, higher symptom burden correlates with peptide dysregulation. A Kyoto University review specifically identifies ghrelin therapy as a potential approach for FD patients with anorexia and weight loss. No approved GI peptide agonist for FD was identified in this dataset.
No approved agent identified · Pipeline stageProbiotics & Duodenal Dysbiosis Correction
A probiotic combination (Lacticaseibacillus rhamnosus LR04, Lactiplantibacillus pentosus LPS01, Lactiplantibacillus plantarum LP01, and Lactobacillus delbrueckii subsp. delbruekii LDD01) administered alone or with prokinetics/PPIs/antacids for 30 days showed clinical improvement in both PDS and EPS symptom domains in an Italian study. A KU Leuven study of duodenal microbiota sequencing in FD patients demonstrated that reduced Porphyromonas levels correlated with symptom severity and duodenal eosinophilia, positioning microbiome composition as both a biomarker and potential therapeutic target. The PatSnap analytics platform enables researchers to track microbiome-targeted patent filings across assignees.
No approved microbiome FD therapy identifiedKey Mechanistic Targets Across the FD Pipeline
Validated and emerging molecular targets identified from clinical trial data, mechanistic studies, and therapeutic guidelines in this dataset.
Muscarinic Receptors / AChE
The acotiamide mechanism — simultaneous M1/M2 muscarinic antagonism enhancing acetylcholine release, combined with AChE inhibition — represents the most clinically validated molecular target in this dataset. Meta-analytic evidence (RR 1.29, 7 RCTs) specifically anchors this target to PDS rather than EPS, highlighting the importance of subtype-stratified trial design.
Gastric Accommodation / Fundal Relaxation Circuitry
Impaired proximal gastric relaxation post-meal is a shared pathophysiological feature documented across multiple retrieved results. DA-9701 addresses this via D2 partial agonism and 5-HT4 agonism simultaneously. Gastric scintigraphy data from Hyogo College of Medicine reveal that gastric accommodation abnormalities are present in a significant proportion of PDS-type FD patients, validating this as a measurable, drug-addressable endpoint.
Duodenal Mucosal Barrier / TEER (EPS-Specific)
Specific to EPS, Tohoku University data showing acid-induced TEER reduction in EPS duodenal biopsies — but not PDS or controls — provide a mechanistic basis for the preferential efficacy of acid suppression in EPS subtypes. This represents a highly subtype-specific target with no approved agent directly addressing barrier function.
Interstitial Cells of Cajal / c-kit Pathway
Retrieved results from Weedahm Oriental Hospital identify ICCs as pacemakers governing GI motility and as targets for herbal compounds that depolarize ICC membranes and upregulate c-kit/stem cell factor expression. This pathway represents an emerging mechanistic rationale for botanical multi-target agents in FD.
FD Drug Pipeline: Agent, Mechanism & Development Stage
Structured pipeline overview derived from clinical trial reports and guideline publications retrieved via PatSnap Eureka.
| Agent | Drug Class | Primary Mechanism | FD Subtype | Stage |
|---|---|---|---|---|
| Acotiamide 100mg TID | Cholinergic prokinetic | M1/M2 antagonism + AChE inhibition | PDS | Approved (Japan, India) |
| Acotiamide ER 300mg QD | Cholinergic prokinetic (ER) | M1/M2 antagonism + AChE inhibition (once-daily) | PDS | Phase III |
| DA-9701 (Motilitone) | Multi-target botanical | D2 partial agonism + 5-HT4 agonism + visceral analgesia | PDS/EPS | Approved (Korea 2011) |
| PPIs (e.g. rabeprazole) | Acid suppressant | Proton pump inhibition | EPS | Established use |
| Vonoprazan (PCAB) | Potassium-competitive acid blocker | K⁺-competitive acid blockade | EPS / NERD overlap | Expanded evaluation |
| Acotiamide + Rabeprazole | Combination regimen | Prokinetic + acid suppression | PDS-GERD overlap | Prospective clinical |
| Probiotic combination (LR04/LPS01/LP01/LDD01) | Microbiome-targeted | Duodenal dysbiosis correction | PDS/EPS | Early clinical |
| Ghrelin / Motilin receptor agonists | GI peptide modulators | Gastric motility enhancement via peptide receptor | PDS (delayed emptying) | Preclinical–early clinical |
Need full assignee and filing data for these agents?
PatSnap Eureka maps patent ownership, clinical trial registrations, and competitive intelligence for every FD drug class.
What the FD Pipeline Signals for Drug Developers & Trialists
PDS vs. EPS stratification is therapeutically decisive. Across retrieved results, acotiamide and gastric motility-targeting agents show consistent efficacy in PDS but not EPS, while acid suppression is preferentially effective in EPS. Drug developers and trialists should systematically enroll by Rome IV subtype to avoid dilution of treatment effects in heterogeneous FD populations.
Acotiamide's extended-release formulation represents an incremental IP and commercial opportunity. Retrieved Phase III data for once-daily acotiamide ER 300 mg demonstrate a viable formulation differentiation strategy that could extend product lifecycle and expand geographic market access beyond Japan. PatSnap IP analytics enables lifecycle management assessment for formulation strategies.
Multi-target mechanisms are gaining mechanistic credibility over single-target approaches. DA-9701's approval and clinical performance relative to itopride signals that compounds simultaneously addressing fundal relaxation, motility, and visceral analgesia may outperform single-mechanism agents in the heterogeneous FD population. According to WHO functional gastrointestinal disorder classifications, this heterogeneity is a defining challenge for the therapeutic area.
Duodenal pathology represents an unmet translational target space. No approved drug in this dataset specifically targets duodenal mucosal barrier function or eosinophil infiltration. Retrieved mechanistic data from Tohoku University and KU Leuven provide a strong scientific basis for anti-eosinophil biologics or microbiome-correcting probiotics as differentiated pipeline candidates. The PatSnap life sciences platform supports target identification across duodenal biology patent clusters.
Combination regimens with acotiamide represent an underexplored clinical development pathway. Retrieved results demonstrate clinical benefit of acotiamide combined with PPIs in GERD/FD overlap and refractory NERD, but no dedicated, adequately powered combination RCT in pure FD-PDS was identified — representing a gap that could support both academic and commercial development programs, particularly in Asia.
Functional Dyspepsia Drug Pipeline — key questions answered
Functional dyspepsia (FD) affects approximately 1 in 10 individuals globally and is classified under the Rome IV criteria into two principal subtypes — postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) — each underpinned by distinct pathophysiological mechanisms.
Acotiamide is a first-in-class muscarinic receptor antagonist and acetylcholinesterase inhibitor that enhances acetylcholine release at the gastric neuromuscular junction. Unlike dopamine D2 or serotonin receptor-targeting prokinetics, acotiamide operates selectively within the stomach through dual cholinergic enhancement, resulting in improved gastric accommodation and accelerated emptying.
A pivotal Phase III placebo-controlled trial showed that acotiamide 100 mg three times daily achieved a responder rate of 52.2% versus 34.8% for placebo in overall treatment effect assessment of meal-related symptoms. A systematic review and meta-analysis pooling seven RCTs demonstrated a summary risk ratio of 1.29 (95% CI: 1.19–1.40, p<0.00001) for overall FD symptom improvement with acotiamide versus placebo, with the effect driven by PDS (RR 1.29; 95% CI: 1.09–1.53) rather than EPS (RR 0.92; NS).
Under Rome IV, PDS prevalence increases to 64% (versus 38% under Rome III) while overlap with EPS decreases to 17% (versus 43%), suggesting Rome IV better isolates distinct pathophysiological entities for targeted therapeutic approaches.
DA-9701 acts through multiple simultaneous mechanisms: prokinetic effects, fundus relaxation via dopamine D2 partial agonism and 5-HT4 agonism, visceral analgesia, and antinociception. A non-inferiority multicenter trial showed DA-9701 (30 mg TID) was non-inferior to itopride (50 mg TID) across 464 FD patients over 4 weeks, with comparable improvement in composite dyspeptic symptom scores.
Acid suppression is more effective in EPS than PDS, mechanistically explained by EPS-specific duodenal mucosal barrier vulnerability to acidic pH. The 2021 Japanese Society of Gastroenterology evidence-based clinical practice guidelines endorse acid suppression as a treatment for FD, with PPIs recommended particularly for EPS.
Still have questions about the FD drug pipeline? Let PatSnap Eureka answer them with live patent and literature data.
Ask PatSnap Eureka About FD TherapiesAccelerate Your Functional Dyspepsia Research with AI-Powered Drug Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map drug pipelines, identify molecular targets, and track competitive assignees across 2B+ patent and literature records.
References
- Epidemiology and Clinical Characteristics Based on the Rome III and IV Criteria of Japanese Patients with Functional Dyspepsia — Hyogo College of Medicine, 2022
- The Application of the Rome IV Criteria to Functional Esophagogastroduodenal Disorders in Asia — Keio University School of Medicine, 2017
- The Impact of Duodenal Mucosal Vulnerability in the Development of Epigastric Pain Syndrome in Functional Dyspepsia — Tohoku University Graduate School of Medicine, 2022
- Functional dyspepsia: new insights into pathogenesis and therapy — University of Newcastle Australia, 2016
- Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia — KU Leuven, 2021
- Ghrelin and Functional Dyspepsia — Kyoto University Hospital, 2010
- Interstitial Cells of Cajal: Potential Targets for Functional Dyspepsia Treatment Using Medicinal Natural Products — Weedahm Oriental Hospital, Seoul, 2021
- A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia — Sakura Life Clinic, Japan, 2011
- Efficacy and Safety of Acotiamide for the Treatment of Functional Dyspepsia: Systematic Review and Meta-Analysis — Sichuan Academy of Medical Sciences, 2014
- Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal-related Symptoms of Functional Dyspepsia, 2018
- Efficacy and Safety of Acotiamide Versus Mosapride in Patients With Functional Dyspepsia Associated With Meal-Induced Postprandial Distress Syndrome: A Phase III Randomized Clinical Trial — King George Hospital, Andhra Medical College, 2021
- Efficacy of Orally Administered Acotiamide Extended-Release Tablets Among Functional Dyspepsia-Postprandial Distress Syndrome Patients — Gandhi Hospital, Secunderabad, 2021
- DA-9701: A New Multi-Acting Drug for the Treatment of Functional Dyspepsia — Dong-A ST Research Institute, Korea, 2013
- Randomized, Controlled, Multi-center Trial: Comparing the Safety and Efficacy of DA-9701 and Itopride Hydrochloride in Patients With Functional Dyspepsia — Wonkwang University College of Medicine, 2015
- Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study — Wonkwang University College of Medicine, 2016
- Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia — Juntendo University, 2016
- A multicenter randomized trial comparing rabeprazole and itopride in patients with functional dyspepsia in Japan: the NAGOYA study — Okazaki City Medical Association, 2017
- Efficacy of serotonin receptor agonists in the treatment of functional dyspepsia: a meta-analysis — Hangzhou Seventh People's Hospital, 2019
- Exploratory Study of Tegaserod for Dyspepsia in Women Receiving PPIs for Heartburn — University of Wisconsin, 2008
- The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review — KU Leuven, 2020
- World Health Organization (WHO) — Functional Gastrointestinal Disorder Classifications
- National Institutes of Health / PubMed — Functional Dyspepsia Clinical Literature Database
- Rome Foundation — Rome IV Diagnostic Criteria for Functional Gastrointestinal Disorders
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.